Answers are grounded in this paper and cite their sources.
Background and Objectives: The clinicopathological characteristics and prognostic significance of HER2-low breast cancer remain controversial. This study compared HER2-zero, HER2-low, and HER2-positive breast cancers and evaluated the independent association between HER2 expression status and survival outcomes. Materials and Methods: This retrospective cohort study included 1535 patients who underwent breast cancer surgery between 2010 and 2022. Patients were classified as HER2-zero (n = 915), HER2-low (n = 359), or HER2-positive (n = 261). Overall survival (OS) and disease-free survival (DFS) were evaluated using Kaplan–Meier analysis and multivariable Cox proportional hazards regression. Models were adjusted for established clinicopathological factors. Results: HER2-low tumors accounted for 23.4% of the cohort and differed from the other HER2 groups in several clinicopathological characteristics, particularly hormone receptor status and proliferative activity. No statistically significant differences were observed among the three groups in OS (log-rank p = 0.114) or DFS (log-rank p = 0.446). In the adjusted full-cohort analyses, HER2-low status was not significantly associated with OS (adjusted hazard ratio [aHR] = 1.209, 95% confidence interval [CI]: 0.830–1.761; p = 0.323) or DFS (aHR = 1.174, 95% CI: 0.844–1.633; p = 0.341), compared with HER2-zero disease. Within the HER2-low subgroup, comorbidities, vascular invasion, perineural invasion, and sentinel/axillary lymph node status were associated with OS, whereas endocrine therapy status and sentinel/axillary lymph node findings were associated with DFS. Among patients receiving neoadjuvant chemotherapy, pathological complete response rates were 14.8%, 21.6%, and 40.0% in the HER2-zero, HER2-low, and HER2-positive groups, respectively. Conclusions: Although HER2-low breast cancer exhibited distinct clinicopathological characteristics, HER2-low status was not independently associated with OS or DFS in this retrospective cohort. These findings suggest that HER2-low classification alone may have limited prognostic value, although prospective studies are needed to confirm these observations.
No takes yet. Share an insight, caveat, or question.
Jafarli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: